P Pu ur rp po os se e: : To investigate the effects of different alfentanil target-concentrations on hemodynamics, respiration and conditions of tracheal intubation during an inhalation induction with 8% sevoflurane.
(Group 75), starting five minutes before induction of anesthesia with 8% sevoflurane in 50% nitrous oxide. The ease of intubation was determined on fixed criteria and scored; arterial pressure, heart rate and bispectral index (BIS) were recorded at one-minute intervals.
R Re es su ul lt ts s: : Times to allow tracheal intubation were shortened only in Group 75 (94 ± 8 sec) as compared to Group 0 (140 ± 11 sec, P < 0.05). BIS values, tracheal intubation scores and number of attempts were not different between groups. However, more patients suffered from apnea in Group 75. Heart rate and mean arterial pressure remained stable in Group 75 whereas they increased significantly in the three other groups. No patient suffered hypotension.
C Co on nc cl lu us si io on n: : Adding alfentanil at a 75 ng·mL -1 target-concentration during an inhalation induction with 8% sevoflurane in 50% nitrous oxide allows intubation slightly earlier and provides stable hemodynamic conditions but the incidence of apnea during induction is higher. Lower concentrations are of little clinical interest. NHALATION induction with sevoflurane is gaining popularity in adults, because tracheal intubation may be performed without muscle relaxants, spontaneous ventilation is better maintained than after an iv induction and loss of consciousness is as rapid.
Objectif : Rechercher les effets de différentes concentrations cibles d'alfentanil sur l'hémodynamique, la respiration et les conditions d'intubation endotrachéale pendant l'induction par inhalation de sévoflu-rane à 8 %.

Méthode
1,2 However, because heart rate may be severely increased, inhalation induction carries the risk of myocardial ischemia in patients at risk. [3] [4] [5] Furthermore, time to tracheal intubation or laryngeal mask insertion is delayed. 1, 6 Because opioids decrease sevoflurane minimum alveolar concentration (MAC) and heart rate, they may reduce hemodynamic changes and time to tracheal intubation. [7] [8] [9] [10] However asystole or severe hypotension may occur, probably because of inappropriate opioid dosing, and the effects of sevoflurane-alfentanil on the ease and speed of tracheal intubation have not been evaluated. 9, [11] [12] [13] Our study aimed to determine the dose of alfentanil required to decrease the time to tracheal intubation and blunt the increase in heart rate associated with an inhalation induction.
M Me et th ho od ds s After Ethical Committee approval and written informed consent, 40 adult ASA physical status I patients were included in this prospective open-label randomized study. At the time of inclusion, patients were instructed on how to perform vital capacity breathing. Two hours before surgery they received 1 mg·kg -1 hydroxyzine. All patients were monitored with an electrocardiogram, pulse oximeter, non-invasive blood pressure device, and bispectral index (BIS; frontal montage, Aspect-1000, Aspect Medical System Inc., Framingham, MA, USA). According to the computerized randomization displayed in sealed envelopes, patients received during the five-minute preceding sevoflurane inhalation, one of the four following alfentanil plasma target-concentrations (Scott weight-adjusted pharmacokinetics model, Stanpump): 0 ng·mL -1 (Group 0), 25 ng·mL -1 (Group 25), 50 ng·mL -1 (Group 50) and 75 ng·mL -1 (Group 75). During this five-minute period, patients received oxygen 8 L·min -1 through a facemask. This five-minute period equals five times the alfentanil blood-brain equilibration half-life, which permits equilibrium of alfentanil concentration between blood and brain. Anesthesia was then induced by asking the patient to perform a vital capacity through a face mask connected to a circle system pre-filled with 8% sevoflurane in 50% N 2 O at a 12 L·min -1 fresh gas flow. Patients were asked to repeat the vital capacity whenever necessary. Time to loss of eyelash reflex and drop of a pen held in the right hand were measured. Tracheal intubation was attempted as soon as the following criteria were obtained: loss of consciousness, mandibular relaxation allowing the insertion of an oropharyngeal airway, BIS < 60 and when the patient tolerated two manual lung inflations. Time to obtain all these criteria defined the theoretical delay to intubation. The number of attempts at tracheal intubation and time to completion were noted for all patients. The conditions of tracheal intubation were graded according to fixed criteria (Table I) . Rocuronium bromide 0.6 mg·kg -1 was injected if one of the following events occurred: apnea and inability to ventilate the patient, laryngospasm or closed vocal cords at time of intubation, cough severe enough to induce hypoxemia (SpO 2 < 93%). Heart rate, blood pressure, SpO 2 , BIS values, respiratory rate and end-tidal sevoflurane concentrations were recorded before and each minute following the beginning of the alfentanil infusion and until the fifth minute following tracheal intubation. Immediately after tracheal intubation, 5 mL of venous blood were collected to measure serum alfentanil concentration by gas chromatography-mass spectrometry (lower limit of detection: 5-10 ng·mL -1 , linearity range: 10-500 ng·mL -1 ). Assuming a (3.7-5.7) min confidence interval for time to intubation without alfentanil, a sample size of ten patients per group can demonstrate by two twotailed t tests with an α error of 0.05 and a ß error of 0.80, a 1.3 min decrease in time to tracheal intubation in one group receiving alfentanil. 6 Data are presented as mean ± SD. Differences vs baseline values were used to compare hemodynamic data. Data were compared by ANOVA followed by t tests when normally distributed (P > 0.05 by Bartlett tests) or Mann Whitney U tests otherwise. A Bonferroni correction was used for t tests when ANOVA was not significant. Qualitative data were compared using exact Fisher tests for multiple groups.
R Re es su ul lt ts s Demographic data were normally distributed and not different between groups (Table II) . Time to loss of eyelash reflex, to drop a pen and to obtain a BIS < 60 were not influenced by any of the alfentanil concentrations. However criteria for tracheal intubation were reached and intubation performed earlier in patients receiving the highest alfentanil target-concentration (Table III) . Once criteria were reached, tracheal intubation was achieved at a similar speed and after a similar number of attempts in the four groups (Tables III  and IV) . During laryngoscopy, mandible relaxation was rated excellent in all patients whether they received or not an opioid. However, in 5/10 patients I receiving the highest alfentanil concentration, vocal cord opening was not optimal and/or apnea lasted more than two minutes. Whatever the target-concentration, alfentanil was unable to suppress the cough reflex following tracheal intubation or cuff inflation (Table IV) .
As compared to baseline, variations of heart rate were significant one minute after the beginning of sevoflurane induction in patients receiving either no opioids or a 25 ng·mL -1 alfentanil concentration whereas heart rate remained unchanged in the two (9) 165 (6) 171 (9) Mean (SD). Mean ± SD. *P < 0.05 as compared to group 0. N/A = not applicable. Figure 1a ) and mean arterial pressure (mmHg; Figure 1b) variations from baseline. Mean ± SD. *P < 0.05 as compared to control group. Pre-anesth = before anesthesia; 5' alf = five minutes after the beginning of alfentanil infusion; 1' sevo and 5' sevo = one minute and five minutes after the beginning of sevoflurane inhalation; pre OTI and post OTI = immediately before and after tracheal intubation; 1 min to 5 min = one minute to five minutes after tracheal intubation.
TABLE IV Characteristics of tracheal intubation
Scores Group 0 Group25 Group 50 Group 75
other groups (Figure 1a) . Before tracheal intubation, heart rate variations reached 25.4 ± 7.9 min -1 in the control group, 23.1 ± 4.1 min -1 in Group 25 (P > 0.05 as compared to Group 0), 7.5 ± 6.7 min -1 in Group 50 (P = 0.08 vs Group 0) and -1.8 ± 4.7 min -1 in Group 75 (P = 0.005 vs Group 0). Immediately and one minute after tracheal intubation, heart rate increased significantly vs baseline in all groups except in patients receiving the 75 ng·mL -1 alfentanil targetconcentration. In these latter patients, heart rate remained stable thereafter and significantly lower than in Group 0 (Figure 1a) .
At the beginning of sevoflurane inhalation, mean arterial pressure differences vs baseline were significant in all groups, without any difference between them (Figure 1b) . Immediately after tracheal intubation, the mean arterial pressure increase was significant in all patients except in those receiving 75 ng·mL -1 alfentanil plasma-target-concentration. In these patients, arterial pressure remained stable until the fourth minute following tracheal intubation (Figure 1b) . The systolic and diastolic arterial pressure variations were similar to those observed for mean arterial pressure (not shown). No decrease in arterial pressure or heart rate higher than 30% of preanesthetic values were observed. However 8/10 patients of Group 0, 9/10 of Group 25, 6/10 of Group 50 and 4/10 of Group 75 increased their heart rate or arterial pressure above 30% of baseline. In Group 75, this increase, only observed after tracheal intubation, was always brief. BIS values are reported in Figure 2 and alfentanil concentrations in Table III. D Di is sc cu us ss si io on n Our study shows that a 75 ng·mL -1 plasma target-concentration of alfentanil is able to blunt the tachycardia observed during an inhalation induction with sevoflurane and following tracheal intubation. Whereas the increase in heart rate is of little consequence in young ASA class I patients, it may be deleterious in older and cardiovascular disabled patients. 4 This study confirms the clinical synergy between low dose alfentanil and sevoflurane. Dahan et al. demonstrated that maximum synergy between sevoflurane and alfentanil on heart rate occurs at an alfentanil plasma concentration as low as 50 ng·mL -1 . 10 In the present study, this alfentanil concentration was measured in patients receiving the 75 ng·mL -1 target-concentration. Our results suggest that a higher alfentanil concentration is not required to blunt the increase in heart rate related to high sevoflurane concentrations or tracheal intubation.
Our study shows that the addition of alfentanil 75 ng·mL -1 to a sevoflurane induction hastens slightly, approximately by 30%, the occurrence of a BIS < 60 and tracheal intubation. Unexpectedly, this effect was slight with no clear dose-effect relationship between the time to obtain the appropriate criteria for intubation and the various concentrations of alfentanil. Indeed, the addition of high opioid doses during steady state conditions reduces by approximately 50% to 80% the various MACs of sevoflurane, which should accelerate induction and tracheal intubation. For example, 3 ng·mL -1 fentanyl reduced by 66% the MAC and by 83% the MAC-BAR of sevoflurane.
14 Sevoflurane ED 95 for tracheal intubation is reduced by 50% and reaches 3.2% when a 1 µg·kg -1 bolus of remifentanil is associated with sevoflurane. 9 While maintaining a steady state concentration of sevoflurane, the MAC for tracheal intubation is reduced by 42% when adding 1 µg·kg -1 fentanyl. 8 The maintenance of a steady state concentration of sevoflurane used in these previous studies is relevant only for maintenance of anesthesia but not for induction. In the present study, we chose a different approach, maintaining alfentanil at steady state concentrations. Indeed, during an inhalation induction, end-tidal, blood and cerebral concentrations of sevoflurane increase rapidly with, approximately, a two-minute half time to equilibrium between blood and brain. 15 This suggests that, during a mask induction, it is probably not possible to reduce the time to tracheal intubation to less than two minutes, without a risk of awareness. This may explain why, during an inhalation induction, alfentanil cannot reduce the time to loss of consciousness.
11 Alfentanil pre-treatment was, as well, unable to reduce consistently the time to obtain a BIS < 60 probably because of this lag and because alfentanil plasma concentrations as high as 50 ng·mL -1 have no effect on BIS during sevoflurane anesthesia. 10 Errors of the pharmacokinetic model due to low target-concentrations of alfentanil may also explain the lack of a dose-effect on intubation times. Low opioid target-concentrations were chosen to preserve spontaneous ventilation because of a synergistic effect between alfentanil and sevoflurane on respiratory depression. 10 Unequal mean prediction errors of alfentanil concentrations may have attenuated the dose-effect relationship. Although the Scott pharmacokinetics model performs well to predict alfentanil concentrations during maintenance, this model has not been validated during the induction of anesthesia. 16, 17 Unfortunately no model specific to induction is available.
Clinical interpretation of the criteria used to decide on tracheal intubation may also have influenced our results. During an inhalation induction, intubation is performed either after a fixed delay and/or according to (subjective) clinical signs such as mandible relaxation and Guedel criteria. A minimal five-minute delay is usually recommended before intubation is attempted. 6 The time to allow intubation was much shorter in this study, even in patients not receiving alfentanil, probably because fixed criteria were used. These were, perhaps, insufficient to evaluate the depth of anesthesia even if they predict the success of laryngeal mask insertion with a sensitivity of 100%. 1, 18 Although this study was unblinded, the same number of attempts, as well as the same time to tracheal intubation, suggest that the criteria were followed equally in all groups. The high incidence of cough after tracheal intubation and after cuff inflation indicates that the airway remained highly reactive whatever the concentration of alfentanil. The maintenance of such a high tracheal reactivity during induction with high concentrations of sevoflurane contradicts a previous report where 1 MAC of sevoflurane was able to suppress the cough response to cuff inflation during maintenance in 30/32 patients. 19 Whereas beneficial on heart rate and time to allow tracheal intubation, the highest concentration of alfentanil was associated with a 50% incidence of prolonged apnea. This apnea occurred mainly after tracheal intubation and, fortunately, was not associated with hypoxemia. This effect of opioids is well-known but was not expected with the low doses of alfentanil used in this study (about 10 µg·kg -1 alfentanil had been administered in ten minutes at the time of tracheal intubation in Group 75). Furthermore, at the highest alfentanil target-concentration, vocal cord opening was incomplete in half the cases and severe cough was observed. As a consequence, neuromuscular blockade remained necessary in three patients receiving the highest alfentanil concentration.
In summary, during 8% sevoflurane inhalation induction, a 75 ng·mL -1 alfentanil plasma target-concentration provides better stability of heart rate and arterial pressure than lower concentrations. Time to allow tracheal intubation is shortened slightly with the 75 ng·mL -1 alfentanil target-concentration. However alfentanil is unable to suppress cough reflex and the incidence of apnea is increased. The use of alfentanil 75 ng·mL -1 may be of clinical interest in patients at risk of cardiac complications. According to the Scott pharmacokinetics model, such a target-concentration may be obtained in 1.5 min after a 7 µg·kg -1 alfentanil infusion.
